Which outcomes are most important to measure in patients with COVID-19 and how and when should these be measured? Development of an international standard set of outcomes measures for clinical use in patients with COVID-19: a report of the International Consortium for Health Outcomes Measurement (ICHOM) COVID-19 Working Group
Joel J Gagnier,
Eyal Zimlichman,
Anne-Marie Russell,
Nick Sillett,
Luz Fialho,
Philip Collis,
William H Seligman,
Kees Brinkman,
Christina Nielsen,
Farhala M Baloch,
Ingel K M Demedts,
Marcelo P Fleck,
Maiara A Floriani,
Lucinda E K Gabriel,
Anju Keetharuth,
Ana Londral,
Ingvar I L Ludwig,
Carlos Lumbreras,
Alejandro Moscoso Daza,
Nasreen Muhammad,
Gisele A Nader Bastos,
Christine W Owen,
John H Powers,
Michaela K Smith,
Tracy Y-P Wang,
Evan K Wong,
Douglas C Woodhouse
Affiliations
Joel J Gagnier
Norwegian Knowledge Centre for the Health Services, Oslo, Norway
Eyal Zimlichman
Sheba Medical Center, Tel Hashomer, Israel
Anne-Marie Russell
Interstitial Lung Disease Unit, Royal Devon University Healthcare NHS Foundation Trust, Exeter, Devon, UK
Nick Sillett
International Consortium for Health Outcomes Measurement, Boston, Massachusetts, USA
Luz Fialho
International Consortium for Health Outcomes Measurement, Boston, Massachusetts, USA
Philip Collis
2 Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK
William H Seligman
International Consortium for Health Outcomes Measurement, Boston, Massachusetts, USA
Kees Brinkman
Department of Internal Medicine, OLVG, Amsterdam, Netherlands
Christina Nielsen
International Consortium for Health Outcomes Measurement, Boston, Massachusetts, USA
Farhala M Baloch
The Aga Khan University Hospital, Karachi, Pakistan
Ingel K M Demedts
AZ Delta Campus Brugsesteenweg, Roeselare, West-Vlaanderen, Belgium
Marcelo P Fleck
Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
Maiara A Floriani
Hospital Moinhos de Vento, Porto Alegre, Brazil
Lucinda E K Gabriel
King’s Health Partners, London, London, UK
Anju Keetharuth
The University of Sheffield, Sheffield, UK
Ana Londral
Value for Health CoLAB, Lisboa, Portugal
Ingvar I L Ludwig
Hospital do Coracao, Sao Paulo, Brazil
Carlos Lumbreras
Universidad Complutense de Madrid, Madrid, Spain
Alejandro Moscoso Daza
Clinica del Country, Bogota, Colombia
Nasreen Muhammad
The Aga Khan University Hospital, Karachi, Pakistan
Gisele A Nader Bastos
Hospital Moinhos de Vento, Porto Alegre, Brazil
Christine W Owen
NHS Wales, Cardiff, UK
John H Powers
professor
Michaela K Smith
Mediclinic Southern Africa, Stellenbosch, South Africa
Tracy Y-P Wang
Duke University School of Medicine, Durham, North Carolina, USA
Objectives The COVID-19 pandemic has resulted in widespread morbidity and mortality with the consequences expected to be felt for many years. Significant variation exists in the care even of similar patients with COVID-19, including treatment practices within and between institutions. Outcome measures vary among clinical trials on the same therapies. Understanding which therapies are of most value is not possible unless consensus can be reached on which outcomes are most important to measure. Furthermore, consensus on the most important outcomes may enable patients to monitor and track their care, and may help providers to improve the care they offer through quality improvement. To develop a standardised minimum set of outcomes for clinical care, the International Consortium for Health Outcomes Measurement (ICHOM) assembled a working group (WG) of 28 volunteers, including health professionals, patients and patient representatives.Design A list of outcomes important to patients and professionals was generated from a systematic review of the published literature using the MEDLINE database, from review of outcomes being measured in ongoing clinical trials, from a survey distributed to patients and patient networks, and from previously published ICHOM standard sets in other disease areas. Using an online-modified Delphi process, the WG selected outcomes of greatest importance.Results The outcomes considered by the WG to be most important were selected and categorised into five domains: (1) functional status and quality of life, (2) mental functioning, (3) social functioning, (4) clinical outcomes and (5) symptoms. The WG identified demographic and clinical variables for use as case-mix risk adjusters. These included baseline demographics, clinical factors and treatment-related factors.Conclusion Implementation of these consensus recommendations could help institutions to monitor, compare and improve the quality and delivery of care to patients with COVID-19. Their consistent definition and collection could also broaden the implementation of more patient-centric clinical outcomes research.